Examining the utility of patient-derived xenograft mouse models

Nature Reviews Cancer

Volumn 15, Issue 5, 2015, Pages 311-316

  Aparicio, Samuel ^a   Hidalgo, Manuel ^b   Kung, Andrew L ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; BREAST CANCER; BREAST EPITHELIUM; CANCER MODEL; CANCER MORPHOLOGY; CANCER RESEARCH; CIRCULATING TUMOR CELL; CLINICAL DECISION MAKING; CLONAL VARIATION; EPIGENETICS; GENE EXPRESSION; GENOMICS; HEMATOLOGIC MALIGNANCY; HISTOLOGY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; MINIMALLY INVASIVE PROCEDURE; MOUSE MODEL; NONHUMAN; PATIENT DERIVED XENOGRAFT; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR ENGRAFTMENT; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; EXPERIMENTAL NEOPLASM; GENETICS; HUMAN; MOUSE; NEOPLASM; PATHOLOGY; XENOGRAFT;

ANIMALS; EPIGENOMICS; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; TRANSPLANTATION, HETEROLOGOUS;

EID: 84928537682     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3944     Document Type: Review

References (42)

1. DeRose, Y. S. et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nature Med. 17, 1514-1520 (2011).
2. Zhang, X. et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 73, 4885-4897 (2013).
3. Zhao, X. et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro Oncol. 14, 574-583 (2012).
4. Loukopoulos, P. et al. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 29, 193-203 (2004).
5. Kabos, P. et al. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res. Treat. 135, 415-432 (2012).
6. Eirew, P. et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518, 422-426 (2015).
7. Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399 (2012).
8. Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nature Meth. 11, 396-398 (2014).
9. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005 (2010).
10. Hidalgo, M. et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998-1013 (2014).
11. Reyal, F. et al. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res. 14, R11 (2012).
12. Garrido-Laguna, I. et al. Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin. Cancer Res. 17, 5793-5800 (2011).
13. Martinez-Garcia, R. et al. Transcriptional dissection of pancreatic tumors engrafted in mice. Genome Med. 6, 27 (2014).
14. Kung, A. L. Practices and pitfalls of mouse cancer models in drug discovery. Adv. Cancer Res. 96, 191-212 (2007).
15. Johnson, J. I. et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br. J. Cancer 84, 1424-1431 (2001).
16. Bertotti, A. et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 1, 508-523 (2011).
17. Marangoni, E. et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin. Cancer Res. 13, 3989-3998 (2007).
18. Fichtner, I. et al. Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin. Cancer Res. 14, 6456-6468 (2008).
19. Sivanand, S. et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci. Transl. Med. 4, 137ra75 (2012).
20. Julien, S. et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin. Cancer Res. 18, 5314-5328 (2012).
21. Peterson, J. K. & Houghton, P. J. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur. J. Cancer 40, 837-844 (2004).
22. Hidalgo, M. et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol. Cancer Ther. 10, 1311-1316 (2011).
23. Morelli, M. P. et al. Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft. J. Clin. Oncol. 30, e45-e48 (2012).
24. Garralda, E. Integrated next generation sequencing and avatar mouse models for personalized cancer treatment. J. Clin. Oncol. 13, 2476-2484 (2013).
25. Crystal, A. S. et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346, 1480-1486 (2014).
26. Boven, E. et al. Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res. 52, 5940-5947 (1992).
27. Hammer, S. et al. Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer. Clin. Cancer Res. 16, 1452-1465 (2010).
28. Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324-338 (2015).
29. Gao, D. et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159, 176-187 (2014).
30. Karthaus, W. R. et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 159, 163-175 (2014).
31. Li, X. et al. Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nature Med. 20, 769-777 (2014).
32. Baccelli, I. et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nature Biotech. 31, 539-544 (2013).
33. Vidal, A. et al. Lurbinectedin (PM01183), a new DNA minor groove binder, inhibits growth of orthotopic primary graft of cisplatin-resistant epithelial ovarian cancer. Clin. Cancer Res. 18, 5399-5411 (2012).
34. Lock, R. B., Liem, N. L. & Papa, R. A. Preclinical testing of antileukemic drugs using an in vivo model of systemic disease. Methods Mol. Med. 111, 323-334 (2005).
35. Kalscheuer, H. et al. A model for personalized in vivo analysis of human immune responsiveness. Sci. Transl. Med. 4, 125ra30 (2012).
36. Kreso, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339, 543-548 (2013).
37. Marusyk, A. et al. Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature 514, 54-58 (2014).
38. Bardelli, A. et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 3, 658-673 (2013).
39. Alvarez, R. et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br. J. Cancer 109, 926-933 (2013).
40. Von Hoff, D. D. et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 29, 4548-4554 (2011).
41. Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691-1703 (2013).
42. Krumbach, R. et al. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur. J. Cancer 47, 1231-1243 (2011).